Call a Colleague with Robert M. Genta, MD
Call a Colleague with Evan Dellon, MD, MPH
A Patient’s Journey In Her Own Words
Call a Colleague with Bruce L. Zuraw, MD
EOSINOPHILIC ESOPHAGITIS
One-hour esophageal string test: a nonendoscopic minimally invasive test that accurately detects disease activity in eosinophilic esophagitis.
Ackerman SJ, et al. Am J Gastroenterol. 2019;114(10):1614-1625.
Phenotypic characterization of eosinophilic esophagitis in a large multicenter patient population from the Consortium for Food Allergy Research.
Chehade M, et al. J Allergy Clin Immunol Pract. 2018;6(5):1534-1544.e5.
Mechanisms of disease of eosinophilic esophagitis.
Davis BP, Rothenberg ME. Annu Rev Pathol. 2016;11:365-393.
A phase 3, randomized, 3-part study to investigate the efficacy and safety of dupilumab in adult and adolescent patients with eosinophilic esophagitis: results from part A.
Dellon ES. American College Gastroenterology Conference; October 26, 2020. Abstract LB3.
Diagnosis and treatment of eosinophilic esophagitis.
Gonsalves NP, Aceves SS. J Allergy Clin Immunol. 2020;145(1):1-7.
Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial.
Hirano I, et al. Clin Gastroenterol Hepatol. 2022;20(3);525-534.
Functional lumen imaging probe for the management of esophageal disorders: expert review from the clinical practice updates committee of the AGA Institute.
Hirano I, et al. Clin Gastroenterol Hepatol. 2017;15(3):P325-P334.
Type 2 inflammation in eosinophilic esophagitis: from pathophysiology to therapeutic targets.
Racca F, et al. Front Physiol. 2021;12:815842.
HEREDITARY ANGIOEDEMA
Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States.
Banerji A, et al. Ann Allergy Asthma Immunol. 2020;124(6):600-607.
Hereditary angioedema: new finding concerning symptoms, affected organs, and course.
Bork K, et al. Am J Med. 2006;119(3):267-274.
Hereditary angioedema.
Busse PJ, Christiansen SC. N Engl J Med. 2020;382(12):1136-1148.
Long-term safety and effectiveness of berotralstat for hereditary angioedema: the open-label APeX-S study.
Farkas H, et al. Clin Transl Allergy. 2021;11(4):e12035.
Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema.
Lara-Marquez ML, et al. Clin Exp Allergy. 2018;48(11):1429-1438
sgp120 and the contact system in hereditary angioedema: a diagnostic tool in HAE with normal C1 inhibitor.
Larrauri B, et al. Mol Immunol. 2020;119:27-34.
The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression.
Lumry WR, et al. Allergy Asthma Proc. 2010;31(5):407-414.
Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks.
Riedl MA, et al. Allergy. 2020;75(11):2879-2887.
Ecallantide.
Zuraw B, et al. Nat. Rev Drug Discov. 2010;9(3):189-190.
Hereditary angioedema with normal C1 inhibitor: four types and counting.
Zuraw BL. J Allergy Clin Immunol. 2018;141(3):884-885.
Guidelines
EOSINOPHILIC ESOPHAGITIS
Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference.
Dellon ES, et al. Gastroenterology. 2018;155(4):1022-1033.e10.
AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis.
Hirano I, et al. Gastroenterology. 2020;158(6):1776-1786.
Technical review on the management of eosinophilic esophagitis: a report from the AGA institute and the joint task force on allergy-immunology practice parameters.
Rank MA, et al. Ann Allergy Asthma Immunol. 2020;124(5):424-440.e17.
HEREDITARY ANGIOEDEMA
US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema.
Busse PJ, et al. J Allergy Clin Immunol Pract. 2021;9(1):132-150.
Patient & Clinician Resources
EOSINOPHILIC ESOPHAGITIS
EoE Adaptive Behaviors Poster
American Partnership for Eosinophilic Disorders (Apfed)
Campaign Urging Research for Eosinophilic Disease (CURED)
National Organization for Rare Disorders